RecruitingNot ApplicableNCT07625202

Creatine Supplementation During GLP-1a Therapy

A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy


Sponsor

University of Saskatchewan

Enrollment

40 participants

Start Date

May 25, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss. This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Dietary supplementation during a 12 week resistance-training program (creatine) and Dietary supplementation during a 12 week resistance-training program (placebo) for people with sarcopenia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTDietary supplementation during a 12 week resistance-training program (creatine)

creatine supplementation

DIETARY_SUPPLEMENTDietary supplementation during a 12 week resistance-training program (placebo)

Placebo


Locations(1)

University of Saskatchewan

Saskatoon, SK - Saskatchewan, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07625202


Related Trials